Company news
Vistagen Therapeutics, Inc. news in 2022
Vistagen Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
December 29, 2022
Vistagen to Acquire Pherin Pharmaceuticals
December 20, 2022
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
December 5, 2022
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
November 29, 2022
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
November 16, 2022
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
November 9, 2022
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
November 3, 2022
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
October 18, 2022
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
October 5, 2022
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
September 7, 2022
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
August 10, 2022
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
July 21, 2022
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
June 22, 2022
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
June 21, 2022
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
June 16, 2022
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
June 1, 2022
VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
May 4, 2022
VistaGen Appoints Reid Adler as Chief Legal Officer
May 1, 2022
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
April 11, 2022
VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
February 9, 2022
Calls in 2022
Decks in 2022
- Investor Presentation (November 2022)
Investor deck · 44 slides · Nov 23, 2022
- Investor Presentation (June 2022)
Investor deck · 40 slides · Jun 9, 2022